Moreover, lenvatinib alone suppresses CSCs marked by CD133 and CD44 expression in HCC (44), and this inhibitory effect was presumably enhanced because elacridar could inhibit lenvatinib efflux by inhibiting MDR1 and BCRP transporters, which might account for the above findings. Here, ABCB1 is linked to hepatocellular carcinoma.